PTAB Upholds 2 Genentech Herceptin Patents, Invalidates 1
The Patent Trial and Appeal Board on Wednesday invalidated one patent covering Genentech Inc.'s blockbuster cancer drug Herceptin, but upheld two others being challenged by Hospira Inc., Samsung Bioepis Co. Ltd....To view the full article, register now.
Already a subscriber? Click here to view full article